Andrew

[Andrew @anflan88]

@DutchRojas This isn’t really as simple as people think. GI docs usually schedule patients in hospital when there’s something complicated about the case that makes it not something they’d want to do at their ASC.

[Andrew @anflan88]

@elonmusk @anish_koka 60% indirect cost doesn’t mean 60% overhead. It means overhead is 60% of the direct costs. That’s about 37.5%. Still high but not as high as it sounds at 60-70%.

[Andrew @anflan88]

@Atul_Gawande @icer_review Opioid epidemic has been used to justify the need for alternatives for acute postop pain. But acute postop pain isn’t really part of the problem especially surgeons only give a few days of pills. The main justification for the new pain drug is patients who have severe nausea.

[Andrew @anflan88]

@DrDamluji The limitation is that apixaban is the real control. It has much less bleeding than rivaroxiban.

[Andrew @anflan88]

@bradloncar That and marketing ED pills to young people

[Andrew @anflan88]

@RobertLKruse @DrZammamSaad @AppleHelix The problem is the group that responds to placebo isn’t random. It’s better to just do a run in on placebo for everyone, and then you don’t need to withdraw anyone from the trial. You’re comparing change to after the run in period.

[Andrew @anflan88]

@adamfeuerstein Doesn’t that mean that placebo beat the drug at other sites?

[Andrew @anflan88]

@mbeisen @Biomaven For more general discoveries that are tools or broad technologies, like for instance a Cas9 enzyme for gene therapy, having it in public domain could make it easier for small companies.

[Andrew @anflan88]

@mbeisen @Biomaven Small molecule drugs discovered essentially have composition patents. If the composition claims are in public domain, actually it’s impossible to justify advancing the drug into human trials because there’s nobody to pay for it.

[Andrew @anflan88]

@RNAiAnalyst @AcuitasTx Wasn’t that obvious based on the fact that they were advancing a backup to start dosing immediately after they reported the toxicity? You don’t advance a backup just in case unless you have some info your acting on.

[Andrew @anflan88]

@RNAiAnalyst Nobody has a redundant backup program ready for IND unless they already know the first one has a problem. Why didn’t they just wait for 102 to begin with - they would have been a year late to dose clinical but avoided this fiasco (maybe)

[Andrew @anflan88]

@Pharmdca What happens if monotherapy shows limited responses?

[Andrew @anflan88]

@JessMcManus901 There’s a reason you haven’t heard anything more about it. Ciraparantag had non-specific reversal and lasts too long. May be difficult to reverse the reversal. Not good characteristics for this category.

[Andrew @anflan88]

@DewDiligence @gibsonchiang That assumes they make the same amount per patient per year. If so, yes that would be a good incentive.

[Andrew @anflan88]

@AWhiteND @ProfMJCleveland @LifeSciVC @matthewherper And the hydrocodone tabs cost 20 cents and have been used for decades without issue.

[Andrew @anflan88]

@anandcpatelmdms @LifeSciVC Lower risk for what? 48 hours of hydrocodone is extremely safe, effective, and inexpensive.

[Andrew @anflan88]

@adamfeuerstein @JonathanWosen The main problem is many company’s are using the opioid epidemic to justify the need for non-opioid acute postop pain meds, when in reality there’s no increased risk for chronic opioid use from acute postop pain treatment with opioids. The main use case is to reduce postop nausea

[Andrew @anflan88]

@gerryfsmith @lisamjarvis What does opioid addiction have to do with postop acute pain treatment?

[Andrew @anflan88]

@RNAiAnalyst Vertex hasn’t shown that their target is helpful for a chronic condition that’s traditionally treated by chronic opioids. The last trial was for an indication treated with generics gabapentin or pregabalin.

[Andrew @anflan88]

@RNAiAnalyst There is no link between acute postop pain treatment with Vicodin for 48 hrs and opioid abuse. That hasn’t stopped companies from using ‘reducing opiood abuse’ as a way to raise money to develop non-opioid treatment for acute postop pain